HYDROXYZINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for hydroxyzine hydrochloride and what is the scope of patent protection?

Hydroxyzine hydrochloride is the generic ingredient in five branded drugs marketed by Baxter Hlthcare, Altana, Am Regent, Dr Reddys, Fresenius Kabi Usa, Hospira, Pharmafair, Smith And Nephew, Solopak, Watson Labs, Wyeth Ayerst, Organon Usa Inc, Pfizer, Roerig, Alpharma Us Pharms, Apozeal Pharms, Bionpharma, Chartwell Rx, Hikma, Kv Pharm, Lannett Co Inc, Novitium Pharma, Pai Holdings Pharm, Rising, Able, Actavis Elizabeth, Amneal Pharm, Aurobindo Pharma Ltd, Epic Pharma Llc, Graviti Pharms, Halsey, Heritage, Hetero Labs Ltd Iii, Ivax Pharms, Kvk Tech, Mutual Pharm, Northstar Hlthcare, Nuvo Pharms Inc, Pliva, Prinston Inc, Purepac Pharm, Quantum Pharmics, Sandoz, Somerset Theraps Llc, Strides Pharma Intl, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, and Usl Pharma, and is included in one hundred and six NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for hydroxyzine hydrochloride. Fifty suppliers are listed for this compound.

Summary for HYDROXYZINE HYDROCHLORIDE

US Patents:	0
Tradenames:	5
Applicants:	49
NDAs:	106
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	50
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	34
Patent Applications:	102
What excipients (inactive ingredients) are in HYDROXYZINE HYDROCHLORIDE?	HYDROXYZINE HYDROCHLORIDE excipients list
DailyMed Link:	HYDROXYZINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for HYDROXYZINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
MATClinics	PHASE4
Friends Research Institute, Inc.	PHASE4
Sultan Qaboos University	Phase 4

See all HYDROXYZINE HYDROCHLORIDE clinical trials

Pharmacology for HYDROXYZINE HYDROCHLORIDE

Drug Class	Antihistamine
Mechanism of Action	Histamine Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for HYDROXYZINE HYDROCHLORIDE

N05BB	Diphenylmethane derivatives
N05B	ANXIOLYTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for HYDROXYZINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	HYDROXYZINE HYDROCHLORIDE	hydroxyzine hydrochloride	SYRUP;ORAL	086880-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Solopak	HYDROXYZINE HYDROCHLORIDE	hydroxyzine hydrochloride	INJECTABLE;INJECTION	087591-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pliva	HYDROXYZINE HYDROCHLORIDE	hydroxyzine hydrochloride	TABLET;ORAL	088619-001	Jan 10, 1986	AB	RX	Yes	No

Market Dynamics and Financial Trajectory for Hydroxyzine Hydrochloride

Last updated: February 19, 2026

Hydroxyzine hydrochloride is a first-generation antihistamine and anxiolytic medication primarily used for allergy symptoms, anxiety, nausea, and sleep disorders. It is marketed under brand names such as Vistaril and Atarax. The global market landscape for hydroxyzine hydrochloride is shaped by factors including prescription trends, regulatory policies, patent statuses, and competitive pressures from generics and alternative therapies.

Market Size and Growth Trends

The hydroxyzine hydrochloride segment is part of the larger antihistamine and anxiolytic markets, which globally reached an estimated valuation of USD 8 billion in 2022. The antihistamine segment alone is expected to grow at a compound annual growth rate (CAGR) of approximately 4% from 2023 to 2030, driven by increasing allergy prevalence and mental health awareness. Hydroxyzine accounts for roughly 15-20% of prescriptions within this category, with a significant portion dispensed in outpatient settings.

The compound annual growth rate (CAGR) for hydroxyzine's market share is projected to be steady, at approximately 2.5% over the next five years. Market expansion hinges on prescribing patterns, off-label uses, and the degree of generic penetration.

Regulatory and Patent Environment

Hydroxyzine hydrochloride was first approved in the United States in the 1950s. Its primary patents have long expired, leading to widespread generic availability. Currently, no recent patent protections limit manufacturing or sales in major markets, facilitating price competition and reducing average selling prices.

The absence of patent protection results in increased price sensitivity and limits revenue potential for innovator companies. Nonetheless, new formulations—such as extended-release variants or combination products—may offer patent opportunities that could influence future market dynamics.

Key Market Players

The market features several generic drug manufacturers, including:

• Teva Pharmaceuticals
• Mylan (now part of Viatris)
• Sandoz (a Novartis division)
• Apotex
• Sun Pharmaceutical Industries

Brand-name products like Vistaril and Atarax are primarily dispensed in the United States, where insurance coverage and prescribing habits influence sales volumes.

Market Drivers

1. Growing Allergic Conditions: Rising prevalence of allergic rhinitis, atopic dermatitis, and other hypersensitivity reactions globally increase demand for antihistamines. The WHO reports allergy prevalence exceeding 30% in some populations.

2. Anxiety Treatment Trends: Increasing recognition and treatment of anxiety disorders augment demand for anxiolytics, including hydroxyzine, particularly for short-term relief due to its sedative properties.

3. Off-label Uses: Hydroxyzine is frequently used off-label for insomnia, nausea, and preoperative sedation, expanding its utilization.

4. Generic Competition: Widespread patent expiry has led to increased generic options, exerting downward pressure on prices but maintaining steady sales volumes due to established prescriber familiarity.

Market Challenges

• Preference for Alternative Agents: The availability of newer non-sedating antihistamines (e.g., loratadine, cetirizine) limits hydroxyzine's market share for allergy indications.
• Safety Profile Concerns: Hydroxyzine’s sedative and anticholinergic side effects restrict its use, particularly in elderly populations, favoring alternative drugs with better safety profiles.
• Regulatory Restrictions: Some jurisdictions impose prescribing restrictions or warnings that discourage off-label and broad use.

Financial Trajectory Forecast

Year	Estimated Market Size (USD millions)	Key Drivers	Revenue Outlook
2022	250	Steady prescription volume, generic competition	Stable with slight decline
2025	270	Increased off-label use, emerging formulations	Slight growth due to niche demand
2030	290	Market saturation, competition from newer agents	Near stabilization or decline

Projected revenues for key players, in the absence of patent exclusivity, will continue to decline in some regions, with residual niche demand maintaining modest sales levels.

Investment and R&D Outlook

Current R&D investments focus on optimizing formulations and exploring non-sedating antihistamine alternatives. Efforts to develop new therapeutic indications or combination therapies could offer future growth avenues, though significant breakthroughs are not currently anticipated.

Key Takeaways

• The hydroxyzine hydrochloride market is mature, with no active patent protections, leading to widespread generic availability.
• Market growth hinges on prescribing trends, off-label use, and emerging formulations.
• The primary markets face intense price competition, limiting revenue growth.
• The global allergic and anxiety treatment markets provide steady demand, but shifting preferences toward newer, better-tolerated agents present challenges.
• Long-term prospects are constrained by safety concerns, competition from non-sedating antihistamines, and regulatory restrictions.

FAQs

1. What factors most influence hydroxyzine hydrochloride sales today?
Prescribing habits driven by allergy prevalence and anxiety treatment, alongside off-label uses such as sleep aid and nausea, drive sales. Generic availability and safety profiles also impact market dynamics.

2. How does patent expiration affect market competition for hydroxyzine?
Patent expiry has allowed multiple generic manufacturers to enter the market, significantly reducing prices and limiting revenue for original drug sponsors.

3. Are there ongoing R&D efforts to improve hydroxyzine?
Yes. Developments include new formulations, such as extended-release versions, and investigations into alternative therapeutic uses. However, no major innovations have emerged recently.

4. What are the primary competitive disadvantages of hydroxyzine?
A sedative effect, anticholinergic side effects, and competition from newer antihistamines with better side effect profiles reduce its appeal.

5. What future trends could influence the hydroxyzine market?
Emerging formulations, changing prescription guidelines, and potential new indications could sustain niche demand, but overall growth remains limited due to competing therapies.

---

References

[1] MarketsandMarkets. (2022). Antihistamines Market by Type, Application, Route of Administration, and Region—Global Forecast to 2030.

[2] World Health Organization (WHO). (2019). Global Allergy Report.

[3] U.S. Food and Drug Administration (FDA). (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).

[4] EvaluatePharma. (2022). Prescription Drug Market Trends.

[5] IMS Health. (2021). Healthcare Data and Market Intelligence Reports.